SAFC Completes Manufacturing Expansion in St. Louis
News May 16, 2015
Sigma-Aldrich® Corporation has announced that SAFC® Commercial (www.sigma-aldrich.com/safc), its custom manufacturing services business unit, has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate (ADC) manufacturing. The facility is in final validation and expected to go online as planned in the third quarter of 2015. Once validated, customers will benefit from working with a single supplier from discovery to commercialization.
Designed to meet SafeBridge® category 4 compound handling to safely accommodate usage of highly-active compounds, the St. Louis expansion creates commercial-scale manufacturing capacity for ADCs and other targeted therapies. The expanded capabilities in St. Louis are further enhanced by expanded commercial capacity for highly-active manufacturing and storage at the Company’s Madison, Wis. facility.
SAFC’s offers include cell-line engineering and media, linkers and payloads, along with significant conjugation expertise using both highly-active and non-potent compounds. The St. Louis expansion complements other recent additions in ADC capabilities, including the announcement of SAFC’s ADC ExpressSM service for preclinical ADC and bioconjugation services, and a collaboration with industry leader Baxter BioPharma Solutions for formulation and fill/finish services.
“The ADC market is a growing market, and is expected to expand over the next few years. This strategic expansion is the latest in a series of enhancements in our ADC offering designed to support this important therapeutic area and to help our customers to seamlessly scale ADC production from preclinical to commercial phases,” said Gilles Cottier, President of SAFC.
Cottier continued, “Our offer can bring customers’ molecules to the clinic faster, with the ease of working with one supplier from start to finish. With the added support of our recently launched ADC Express service, we believe SAFC presents the most comprehensive offer in the contract manufacturing market.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019